A phase IIa study of JX 594 in patients with squamous cell head and neck cancer.
Latest Information Update: 06 Nov 2007
Price :
$35 *
At a glance
- Drugs Pexastimogene devacirepvec (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Jennerex
- 06 Nov 2007 New trial record.